Free Trial
NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Price, News & Analysis

Precision BioSciences logo
$7.68 -0.36 (-4.45%)
As of 11:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Precision BioSciences Stock (NASDAQ:DTIL)

Advanced

Key Stats

Today's Range
$7.60
▼
$8.16
50-Day Range
$5.77
▼
$10.60
52-Week Range
$3.53
▼
$11.29
Volume
184,993 shs
Average Volume
323,953 shs
Market Capitalization
$214.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.25
Consensus Rating
Moderate Buy

Company Overview

Precision BioSciences is a biotechnology company developing gene-editing therapies using its proprietary ARCUS platform. The platform is designed to make targeted changes to DNA and is being applied to investigational treatments for genetic and infectious diseases.

The company’s programs include PBGENE-HBV, an investigational therapy designed to target hepatitis B virus DNA, and PBGENE-DMD, a gene-editing program for Duchenne muscular dystrophy. These candidates remain in development and are not approved treatments.

Founded in 2006 and headquartered in Durham, North Carolina, Precision BioSciences has also pursued applications of its gene-editing technology through collaborations and licensing arrangements.

AI Generated. May Contain Errors.

Precision BioSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

DTIL MarketRank™: 
3.293338578545 of 5 stars

Precision BioSciences scored higher than 66% of companies evaluated by MarketBeat, and ranked 269th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Precision BioSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Precision BioSciences has a consensus price target of $32.25, representing about 301.1% upside from its current price of $8.04.

  • Amount of Analyst Coverage

    Precision BioSciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Precision BioSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Precision BioSciences are expected to grow in the coming year, from ($2.28) to ($1.73) per share.

  • Price to Book Value per Share Ratio

    Precision BioSciences has a P/B Ratio of 4.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    7.71% of the float of Precision BioSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Precision BioSciences has a short interest ratio ("days to cover") of 10.52, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Precision BioSciences has recently decreased by 11.03%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Precision BioSciences does not currently pay a dividend.

  • Dividend Growth

    Precision BioSciences does not have a long track record of dividend growth.

  • News Sentiment

    Precision BioSciences has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 16 news articles for Precision BioSciences this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    4 people have added Precision BioSciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Cluster Insider Buying

    3 insiders have purchased shares of Precision BioSciences in the last three months. Multiple insiders buying is a strong bullish signal.

  • Net Insider Buying

    Over the last three months, insiders have purchased a net $29,501.00 in company stock, which represents 0.0131% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Precision BioSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,501.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    2.70% of the stock of Precision BioSciences is held by insiders.

  • Percentage Held by Institutions

    37.99% of the stock of Precision BioSciences is held by institutions.

  • Read more about Precision BioSciences' insider trading history.
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DTIL Stock News Headlines

HC Wainwright Has Bullish Estimate for DTIL FY2026 Earnings
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Headlines

DTIL Stock Analysis - Frequently Asked Questions

Precision BioSciences' stock was trading at $4.16 at the beginning of 2026. Since then, DTIL shares have increased by 93.3% and is now trading at $8.04.

Precision BioSciences, Inc. (NASDAQ:DTIL) released its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.57. Precision BioSciences had a negative trailing twelve-month return on equity of 56.69% and a negative net margin of 96.73%.

Shares of Precision BioSciences reverse split before market open on Wednesday, February 14th 2024.The 1-30 reverse split was announced on Wednesday, February 14th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Precision BioSciences (DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays acted as the underwriters for the IPO.

Precision BioSciences' top institutional shareholders include State Street Corp (1.56%), Russell Investments Group Ltd. (0.30%) and Aberdeen Group plc (0.10%). Insiders that own company stock include Michael Amoroso, John Alexander Kelly, J Jefferson Smith, Geno J Germano, Melinda Brown, Stanley Frankel, Dario Scimeca and Alan List.
View institutional ownership trends
.

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Precision BioSciences investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Kaleido Biosciences (KLDO), Tesla (TSLA), Micron Technology (MU), Advanced Micro Devices (AMD) and CRISPR Therapeutics (CRSP).

Company Calendar

Last Earnings
11/03/2026
Today
11/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DTIL
CIK
1357874
Fax
N/A
Employees
69
Year Founded
2006

Price Target and Rating

High Price Target
$60.00
Low Price Target
$19.00
Potential Upside/Downside
+321.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.72 million
Net Margins
-96.73%
Pretax Margin
-87.54%
Return on Equity
-56.69%
Return on Assets
-27.63%

Debt

Debt-to-Equity Ratio
0.43
Current Ratio
10.47
Quick Ratio
10.47

Sales & Book Value

Annual Sales
$34.26 million
Price / Sales
6.23
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.85 per share
Price / Book
4.13

Miscellaneous

Outstanding Shares
27,940,000
Free Float
27,182,000
Market Cap
$213.60 million
Optionable
Optionable
Beta
1.34

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:DTIL) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners